Despite its broader target speci?city, preparations of C1-INH are the only complement protease inhibitor currently available in the clinic
with a primary indication for the treatment of HAE.
However,
given the safe and successful outcomes that have been achieved in HAE therapy,
C1-INH is now being investigated in trials for several disease states such as
- sepsis (NCT01766414, NCT00785018, 2011-002222-46),
- transplant rejection (NCT01134515, NCT01147302),
- neuromyelitis optica(NMO) (NCT01759602),
- ischemia–reperfusion injury (IRI) (NCT01886443),
- autoimmune hemolytic anemia (2012-003710-13).
Ik zou zeggen, genoeg om van te kiezen.